We’re Hiring! View Open Positions

Pipeline

Compound Disease Phase
Rodatristat ethyl Pulmonary Arterial Hypertension (PAH) Phase 2
Idiopathic Pulmonary Fibrosis (IPF) Research
ALTA-2530 Transplant-associated bronchiolitis obliterans syndrome IND Enabling
Chemical-induced bronchiolitis obliterans syndrome Research
Next-Generation TPH Inhibitors Oral agents for multiple indications Research
Alternative routes of administration for multiple indications Research
Compound Disease Research IND Enabling Phase 1 Phase 2 Phase 3

Rodatristat Ethyl

a peripherally acting TPH inhibitor

Pulmonary Arterial Hypertension (PAH)
Idiopathic Pulmonary Fibrosis (IPF)

ALTA-2530

a treatment for bronchiolitis obliterans syndrome and chemical lung injury

Transplant-associated bronchiolitis obliterans syndrome
Chemical-induced bronchiolitis obliterans syndrome

Partnered with BARDA / NIAID

Next-Generation TPH Inhibitors

Oral agents for multiple indications
Alternative routes of administration of multiple indications

Contact us for more information